Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV

DOI PDF 被引用文献4件
  • Veronique Minard-Colin
    Department of Immunology, Duke University Medical Center, Durham, NC; and
  • Yan Xiu
    Department of Immunology, Duke University Medical Center, Durham, NC; and
  • Jonathan C. Poe
    Department of Immunology, Duke University Medical Center, Durham, NC; and
  • Mayuka Horikawa
    Department of Immunology, Duke University Medical Center, Durham, NC; and
  • Cynthia M. Magro
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY
  • Yasuhito Hamaguchi
    Department of Immunology, Duke University Medical Center, Durham, NC; and
  • Karen M. Haas
    Department of Immunology, Duke University Medical Center, Durham, NC; and
  • Thomas F. Tedder
    Department of Immunology, Duke University Medical Center, Durham, NC; and

説明

<jats:title>Abstract</jats:title><jats:p>Despite the demonstrated clinical efficacy of CD20 monoclonal antibody (mAb) for lymphoma therapy, the in vivo mechanisms of tumor depletion remain controversial and variable. To identify the molecular mechanisms responsible for lymphoma killing by CD20 mAb in a homologous system amenable to mechanistic studies and genetic manipulation, a mouse lymphoma model was developed using primary tumor cells from a C57BL/6 Eμ-cMyc transgenic mouse and mouse antimouse CD20 mAbs. CD20 mAb treatment of syngeneic mice with adoptively transferred lymphomas prevented tumor development or significantly prolonged mouse survival depending on tumor volume, mAb dose, and treatment timing. Cooperative FcγRIV, FcγRIII, and FcγRI interactions mediated optimal lymphoma depletion by CD20 mAb in vivo, whereas clodronate-mediated depletion of macrophages eliminated the therapeutic benefit of CD20 mAb. Although CD20 mAbs activated complement in vitro and in vivo, normal and malignant B-cell depletion was induced through C1q- and C3-independent mechanisms. Thus, the ability of CD20 mAbs to deplete malignant B cells in vivo required FcγR-dependent use of the innate mononuclear cell immune system. These findings allow for mechanism-based predictions of the biologic outcome of CD20 mAb therapy and treatment optimization.</jats:p>

収録刊行物

  • Blood

    Blood 112 (4), 1205-1213, 2008-08-15

    American Society of Hematology

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ